日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension study

鲁马特哌隆 42 mg 治疗双相情感障碍患者的长期安全性和耐受性:一项为期 6 个月的开放标签扩展研究的结果

Tohen, Mauricio; Durgam, Suresh; Kozauer, Susan G; Chen, Changzheng; Davis, Robert E; Mates, Sharon

Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial

鲁马特隆单药治疗双相情感障碍相关重度抑郁发作:一项随机安慰剂对照试验的疗效和安全性

Correll, Christoph U; Durgam, Suresh; Kozauer, Susan G; Lakkis, Hassan D; Chen, Changzheng; Vanover, Kimberly E; Mates, Sharon; Davis, Robert E

Development and Validation of PARCOMS Composite Scales for Assessing Disease Progression and Treatment Effects in Parkinson's Disease

帕金森病疾病进展和治疗效果评估中PARCOMS综合量表的开发与验证

L'Italien, Gil; Rogula, Basia; Powell, Lauren; Potashman, Michele; Dickson, Samuel P; Kozauer, Nick; O'Keefe, Patrick; Korol, Ellen; Crabtree, Madeleine; Nagase, Fernanda; Coric, Vlad; Dubow, Jordan; Rosenthal, Liana S; Hendrix, Suzanne

Lumateperone for the Treatment of Major Depressive Disorder With Mixed Features or Bipolar Depression With Mixed Features: A Randomized Placebo-Controlled Trial

鲁马特隆治疗伴有混合特征的重度抑郁症或伴有混合特征的双相抑郁症:一项随机安慰剂对照试验

Durgam, Suresh; Kozauer, Susan G; Earley, Willie R; Chen, Changzheng; Huo, Jason; Lakkis, Hassan; Stahl, Stephen; McIntyre, Roger S

F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA

F46. 鲁马特哌隆 (ITI-007):在一项开放标签的安全性转换研究中,从精神分裂症患者的标准抗精神病药物治疗转换至鲁马特哌隆,结果显示其安全性良好

Heilbron, Nicole; Compton, Jill S; Daniel, Stephanie S; Goldston, David B; Rosén Rasmussen, Andreas; Parnas, Josef; Hilker, Rikke; Nielsen, Jimmi; Nielsen, Mette Ødegaard; Pillinger, Toby; McCutcheon, Rob; Efthimiou, Orestis; Cipriani, Andrea; Howes, Oliver; Wijtenburg, Andrea; Korenic, Stephanie; Chen, Hongji; Sewell, Jessica; Elliot Hong, L; Rowland, Laura; Lindgren, Maija; Jonninen, Minna; Jokela, Markus; Therman, Sebastian; Bonivento, Carolina; Urquijo, Maria Fernanda; Borgwardt, Stefan; Meisenzahl, Eva; Rosen, Marlene; Salokangas, Raimo; Upthegrove, Rachel; Wood, Stephen; Koutsouleris, Nikolaos; Brambilla, Paolo; Davis, Robert; Dmitrienko, Alex; Glass, Steven; Kozauer, Susan; Saillard, Jelena; Weingart, Michal; Satlin, Andrew; Mates, Sharon; Correll, Christoph; Vanover, Kimberly

Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development

阿尔茨海默病神经病理学背景下的多种共病神经病理学及其对药物研发的影响

Rabinovici, Gil D; Carrillo, Maria C; Forman, Mark; DeSanti, Susan; Miller, David S; Kozauer, Nicholas; Petersen, Ronald C; Randolph, Christopher; Knopman, David S; Smith, Eric E; Isaac, Maria; Mattsson, Niklas; Bain, Lisa J; Hendrix, James A; Sims, John R

The roles of inflammation and immune mechanisms in Alzheimer's disease

炎症和免疫机制在阿尔茨海默病中的作用

Van Eldik, Linda J; Carrillo, Maria C; Cole, Patricia E; Feuerbach, Dominik; Greenberg, Barry D; Hendrix, James A; Kennedy, Matthew; Kozauer, Nick; Margolin, Richard A; Molinuevo, José L; Mueller, Reinhold; Ransohoff, Richard M; Wilcock, Donna M; Bain, Lisa; Bales, Kelly

Considerations for the assessment of suicidal ideation and behavior in older adults with cognitive decline and dementia

对认知能力下降和痴呆症老年人自杀意念和行为评估的考量因素

Alphs, Larry; Brashear, H Robert; Chappell, Phillip; Conwell, Yeates; Dubrava, Sarah; Khin, Ni A; Kozauer, Nicholas; Hartley, Dean M; Miller, David S; Schindler, Rachel J; Siemers, Eric R; Stewart, Michelle; Yaffe, Kristine

Regionally-specific diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease

轻度认知障碍和阿尔茨海默病中的区域特异性弥散张量成像

Mielke, M M; Kozauer, N A; Chan, K C G; George, M; Toroney, J; Zerrate, M; Bandeen-Roche, K; Wang, M-C; Vanzijl, P; Pekar, J J; Mori, S; Lyketsos, C G; Albert, M

Psychiatric manifestations of neurologic disease: where are we headed?

神经系统疾病的精神症状:我们将走向何方?

Lyketsos, Constantin G; Kozauer, Nicholas; Rabins, Peter V